Cyclopharm Limited (ASX:CYC)
Australia · Delayed Price · Currency is AUD 0.5050
-0.0050 (-0.98%)
Sep 2, 2026, 1:39 PM AEST
Cyclopharm Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 34.42 | 32.33 | 27.57 | 26.34 | 22.88 | 17.7 |
Other Revenue | - | - | - | - | 1.98 | 2.29 |
| 34.42 | 32.33 | 27.57 | 26.34 | 24.85 | 20 | |
Revenue Growth | 12.05% | 17.24% | 4.68% | 5.97% | 24.30% | 13.09% |
Cost of Revenue | 14.97 | 14.47 | 9.64 | 10.26 | 7.44 | 5.04 |
Gross Profit | 19.46 | 17.85 | 17.93 | 16.08 | 17.41 | 14.95 |
Selling, General & Admin | 34.66 | 33.65 | 30.62 | 21.48 | 18.69 | 16.68 |
Research & Development | 0.9 | 0.61 | 0.37 | 3.69 | 3.44 | 1.66 |
Other Operating Expenses | -0.62 | -0.61 | - | - | 0.35 | 0.52 |
Operating Expenses | 36.61 | 35.42 | 32.46 | 26.11 | 23.41 | 19.61 |
Operating Income | -17.15 | -17.57 | -14.52 | -10.02 | -6 | -4.66 |
Interest Expense | -0.53 | -0.58 | -0.28 | -0.19 | -0.27 | -0.09 |
Interest & Investment Income | 0.18 | 0.3 | 0.67 | 0.49 | 0.11 | 0 |
Earnings From Equity Investments | - | 1.1 | 0.92 | 0.8 | - | - |
Currency Exchange Gain (Loss) | -0.16 | -0.08 | 0.17 | 0.19 | 0.12 | 0.26 |
Other Non Operating Income (Expenses) | -0.06 | -0.05 | -0.04 | -0.02 | - | - |
EBT Excluding Unusual Items | -17.72 | -16.88 | -13.08 | -8.77 | -6.03 | -4.49 |
Gain (Loss) on Sale of Assets | 2.37 | 2.37 | -0 | - | - | - |
Asset Writedown | -3.34 | -3.34 | - | 3.16 | - | - |
Legal Settlements | - | - | - | 1.28 | - | - |
Pretax Income | -18.69 | -17.86 | -13.07 | -4.19 | -6.03 | -4.35 |
Income Tax Expense | -0.37 | -0.64 | 0.13 | 0.51 | 0.58 | 0.69 |
Net Income | -18.32 | -17.22 | -13.2 | -4.7 | -6.61 | -5.04 |
Net Income to Common | -18.32 | -17.22 | -13.2 | -4.7 | -6.61 | -5.04 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 115 | 110 | 103 | 93 | 92 | 90 |
Shares Outstanding (Diluted) | 115 | 110 | 103 | 93 | 92 | 90 |
Shares Change | 4.29% | 7.02% | 11.05% | 0.53% | 2.77% | 17.10% |
EPS (Basic) | -0.16 | -0.16 | -0.13 | -0.05 | -0.07 | -0.06 |
EPS (Diluted) | -0.16 | -0.16 | -0.13 | -0.05 | -0.07 | -0.06 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.18 | -19.32 | -13.38 | -7.43 | -7.94 | -2.47 |
Free Cash Flow Per Share | -0.17 | -0.17 | -0.13 | -0.08 | -0.09 | -0.03 |
Dividend Per Share | - | - | - | 0.005 | 0.010 | 0.010 |
Dividend Growth | - | - | - | -50.00% | 0% | 0% |
Gross Margin | 56.52% | 55.23% | 65.04% | 61.06% | 70.06% | 74.78% |
Operating Margin | -49.82% | -54.36% | -52.68% | -38.06% | -24.13% | -23.31% |
Profit Margin | -53.23% | -53.27% | -47.87% | -17.85% | -26.60% | -25.21% |
Free Cash Flow Margin | -55.73% | -59.77% | -48.52% | -28.23% | -31.94% | -12.36% |
EBITDA | -16.34 | -16.69 | -13.69 | -9.36 | -5.36 | -4.19 |
EBITDA Margin | -47.46% | -51.64% | -49.65% | -35.55% | -21.55% | -20.96% |
D&A For EBITDA | 0.81 | 0.88 | 0.83 | 0.66 | 0.64 | 0.47 |
EBIT | -17.15 | -17.57 | -14.52 | -10.02 | -6 | -4.66 |
EBIT Margin | -49.82% | -54.35% | -52.68% | -38.06% | -24.13% | -23.31% |
Revenue as Reported | - | - | - | 26.34 | 24.96 | 20.14 |
Advertising Expenses | - | 1.28 | 1.47 | 0.98 | 0.54 | 0.3 |